Visioneers, a leading advanced science and technology management consulting and marketing services company, along with Quine Biologics Inc., and StableBody Technologies are pleased to announce the collaboration.
In the rapidly evolving field of immunotherapy, vaccine development, and diagnostics, the precision design of antibodies to target specific epitopes by using three-dimensional (3D) structures is at the forefront of scientific innovation.
In targeted disease treatments, highly stable antibodies are necessary for the development of therapies that retain therapeutic efficacy over time.
Quine Biologics is an expert in structure-based de-novo antibody design therapies that retain therapeutic efficacy over time.
StableBody Technologies is a leader in the field of antibody stabilization and affinity maximization.
The primary sequence, secondary structure information, and numerous variant found in various databases serve as guides for alternative folding solutions.
Next Generation Stable Protein Reagents will be created by the collaboration project.
The binding Kd can be improved by up to 300% for higher sensitivity.
Increasing stability properties, conferring longer shelf life, allowing for increased working temperatures, and eliminating cold chain issues for shipping and storage are some of the things that have been improved.
Reducing costs and time to market can be achieved by improving production efficiency.
20/15 Visioneers has over 30 years of experience in scientific management consulting.
The source is 20/15 Visioneers.
Visioneers, a leading advanced science and technology management consulting and marketing services company, and MilkingCloud, a leader...

Source prnewswire